Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06790602 · ClinicalTrials.gov registry record · Phase 2
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 2 study of Pancreatic Ductal Adenocarcinoma (mPDAC), sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT06790602: Recruiting Phase 2 study of Pancreatic Ductal Adenocarcinoma (mPDAC), sponsored by University of California, San Diego.
NCT06790602 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma (mPDAC) that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06790602, a Phase 2 study of Pancreatic Ductal Adenocarcinoma (mPDAC), is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose Non-Fermentable (SWI/SNF) alterations who have already been treated with FOLFIRINOX (5-fluoruracil, leucovorin, irinotecan, oxaliplatin) or gemcitabine/nab-paclitaxel chemotherapy.
Primary Outcome
To evaluate the overall survival of participants with metastatic pancreatic adenocarcinoma harboring SWI/SNF alterations treated with cemiplimab in combination with gemcitabine as a second-line treatment.
Conditions Studied
Interventions
- DRUG Cemiplimab Plus Gemcitabine
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2026-01 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
What NCT06790602 shows while recruiting
NCT06790602 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma (mPDAC) appearing as the primary indexed condition, and to 1 intervention - of which Cemiplimab Plus Gemcitabine is the first listed.
NCT06790602 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06790602 about?
NCT06790602 is a clinical study titled "Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma". This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose Non-Fermentable (SWI/SNF) alterations who have already been treated with FOLFIR...
What is the current status of trial NCT06790602?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2026-01. Estimated completion is 2029-12.
What conditions does trial NCT06790602 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma (mPDAC).
What interventions are being tested in trial NCT06790602?
The interventions under investigation include: Cemiplimab Plus Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT06790602?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06790602 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06790602's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia